Business
GlycotestT Completes Diagnostic Evaluation
GlycotestT Completes Diagnostic Evaluation.
About this update from Emv Capital Plc
[{"type":"text","content":"\n \nRNS Number : 8997A NetScientific PLC 04 January 2018 \n\n \n \nNetScientific plc\n(\"NetScientific\" or the \"Company\" or the \"Group\")\n \nGlycotest™ Successfully Completes Clinical Diagnostic Evaluation in Liver Cancer\n \nLondon, UK - 04 January 2018 - NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company Glycotest has successfully completed a clinical evaluation of its diagnostic panel to detect Hepatocellular Carcinoma (HCC), the most common form of liver cancer, in China.\nIn a blind evaluation of 149 HCC positive patients and control samples, Glycotest's HCC Panel achieved an AUROC* of 0.97 and exhibited 93% sensitivity** at 92% specificity***, which indicates a high predictability on a statistical basis as to whether liver cancer is present in patients or not. \nIn the cohort of HCC patients whose tumors had not been detected by an alpha-fetoprotein (AFP) blood test, the most common blood test used for initial liver cancer diagnosis, the HCC Panel was able to identify 86% of patients with liver cancer. In an early-stage cohort of patients with HCC, the HCC Panel was able to identify 78% of patients with liver cancer undetected by AFP.\nNetScientific holds an 87.5% stake (67% on a fully diluted basis) in Glycotest. \n \nCommenting on the news, NetScientific's Chief Executive Officer and Chairman of Glycotest, Francois R. Martelet said: \"We are delighted to announce the success of the Chinese clinical trial, which validates the previous clinical studies performed with a combined total of 335 patients. Given that liver cancer is the fastest growing cause of death in the US and the leading cause of death in China, we believe that the positive outcome of the trial will be very significant for patients suffering with HCC. Commercially, we believe the opportunity to be very attractive, with an estimated total accessible market of $1bn annually.\"\n \nThe full text of the announcement from Glycotest can be found below.\n \nFor more information please contact: \n \nNetScientific \nFrançois R. Martelet, M.D., CEO \nIan Postlethwaite, CFO \nTel: +44 (0)20 3514 1800 \[email protected]\n \nConsilium Strategic Communications \nMary-Jane Elliott / Jessica Hodgson / \nChris Welsh / Laura Thor...